The global biosimilars and follow-on biologics market is estimated to have reached $10.7bn in 2018 and expected to grow at a CAGR of 5.4% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 23% share of this market in 2018.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 283-page report you will receive 98 tables and 67 figures– all unavailable elsewhere.

2 An Introduction to Biosimilars and Biosimilar Drug Development 2.1 What are Biologics? 2.1.1 Biologics can be very effective but also very expensive 2.1.2 Brief history of biological drug development 2.1.3 Why are Biologics the most lucrative products in the global pharmaceutical market? 2.2 What are Biosimilars? 2.3 Brief History of Biosimilars 2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars? 2.4.1 FDA Guidelines on Prescription of Interchangeables vs Biosimilars 2.4.2 Where does the EMA Stand with Regard to Interchangeables? 2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution? 2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars? 2.5 Main Segments of the Overall Biosimilars Market

3 The Global Biosimilars Market 2018-2028 3.1 The Global Biosimilars Market 3.2 Biosimilars as a Share of the Biologics Market, 2017 3.2.1 Seven of the Top Ten Best-Selling Drugs are Biologics 3.2.2 Outlook for the Overall Biologics Market 3.3 Global Biosimilars Market Forecast, 2017-2029 3.4 What will Drive Growth in the Biosimilars Market? 3.4.1 Health benefits associated with biosimilars 3.4.2 Patent related re-issue factors 3.4.3 Supportive government norms related to biosimilars 3.4.4 Growing demand from emerging economies 3.4.5 Increasing research and development activities 3.5 What Factors Can Restrain Sales Growth in the Biosimilars Market? 3.5.1 Complexity in development process 3.5.2 Intense competition 3.5.3 Availability of substitutes like biobetters and next-generation biologics 3.6 Summary of the Drivers and Restraints for the Global Biosimilars Market 3.7 Global Biosimilars Market Forecast by Submarket, 2017-2029 3.7.1 Leading Segments in the Biosimilars Market 3.7.2 How Will the Composition of the Market Change Over the Next Ten Years?

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com